Abbott Laboratories experienced a notable decline in its share price during today’s session, largely driven by investor concerns surrounding the company’s near-term earnings outlook and ongoing litigation risks. The downward pressure appears to be linked to a combination of cautious guidance within the medical devices division and fresh developments in the legal challenges related to its specialized infant formula products. Market participants are recalibrating their expectations as the company navigates a complex regulatory and legal landscape.

The primary catalyst for the intraday volatility stems from the nutrition segment, where legal proceedings regarding necrotizing enterocolitis claims continue to weigh heavily on institutional…